Author:
Barnum Collin R.,Paviani Bruna,Couture Garret,Masarweh Chad,Chen Ye,Huang Yu-Ping,Mills David A.,Lebrilla Carlito B.,Barile Daniela,Yang Minliang,Shih Patrick M.
Abstract
AbstractHuman milk oligosaccharides (HMOs) are a diverse class of carbohydrates that aid in the health and development of infants. The vast health benefits of HMOs have made them a commercial target for microbial production; however, producing the ∼130 structurally diverse HMOs at scale has proven difficult. Here, we produce a vast diversity of HMOs by leveraging the robust carbohydrate anabolism of plants. This diversity includes high value HMOs, such as lacto-N-fucopentaose I, that have not yet been commercially produced using state-of-the-art microbial fermentative processes. HMOs produced in transgenic plants provided strong bifidogenic properties, indicating their ability to serve as a prebiotic supplement. Technoeconomic analyses demonstrate that producing HMOs in plants provides a path to the large-scale production of specific HMOs at lower prices than microbial production platforms. Our work demonstrates the promise in leveraging plants for the cheap and sustainable production of HMOs.
Publisher
Cold Spring Harbor Laboratory
Reference58 articles.
1. Walsh, C. , Lane, J. A. , van Sinderen, D. & Hickey, R. M . Human milk oligosaccharides: Shaping the infant gut microbiota and supporting health. Journal of Functional Foods 72, 104074 (2020).
2. Milk Glycans and Their Interaction with the Infant-Gut Microbiota
3. Human Milk Oligosaccharides: 2′-Fucosyllactose (2′-FL) and Lacto-N-Neotetraose (LNnT) in Infant Formula;Nutrients,2018
4. Wiciński, M. , Sawicka, E. , Gębalski, J. , Kubiak, K. & Malinowski, B . Human Milk Oligosaccharides: Health Benefits, Potential Applications in Infant Formulas, and Pharmacology. Nutrients 12, 266 (2020).
5. CDC. 2022 Breastfeeding Report Card. Centers for Disease Control and Prevention https://www.cdc.gov/breastfeeding/data/reportcard.htm (2022).